This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits

Stocks in this article: AAPL ARIA MNKD NPSP PCYC SHPG IBB XBI

NEW YORK (TheStreet) -- Apple  (AAPL - Get Report) may be Monday's big newsmaker with its Worldwide Developer Conference. But traders on StockTwits.com aren't waiting for Tim Cook and Co. to get started. Instead, they're watching announcements from small drug companies on medication trials and tuning in to rumors about big pharma buyouts.

And, so far today, their attention is paying off. 

The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming | http://stks.co/c0cBX $MNKD $OREX $IBB $BDSI #biotech ? Scott Matusow (@ScottMatusow) Jun. 2 at 08:58 AM

Drug companies Ariad Pharmaceuticals  (ARIA - Get Report), MannKind (MNKD), NPS Pharmaceuticals  (NPSP) and Pharmacyclics  (PCYC) were the top trending tickers on StockTwits.com Monday morning. They were joined on the trending bar of the dozen most discussed stocks by two biotech ETFs, iShares Nasdaq Biotechnology  (IBB) and SPDR S&P Biotech  (XBI).

Apple made the list too, due to hype over what management could reveal about the company's product pipeline and plans for Beats Electronics. But many on StockTwits.com said that excitement was misplaced. Apple, they noted, has a history of disappointing WWDC expectations. The stock has declined after eleven of the past conferences.

$AAPL during WWDC , since 2003 & blog with details -> http://stks.co/g0fqq 11/11 losers for longs http://stks.co/s0Nqd ? Kora Reddy (@paststat) Jun. 1 at 09:35 AM

Investors on StockTwits were most interested in Ariad Pharmaceuticals. The company topped the StockTwits trending ticker bar with news that a drug to treat certain types of gastrointestinal tumors had positive results in early Phase II clinical trials. The FDA is lifting a partial ban that had restricted the company's ability to enroll new human test subjects.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs